Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI South Africa ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.99 (market cap $3.33B), while iShares MSCI South Africa ETF trades at $62.38. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | EZA | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $81.60 |
52-Week Low | $10.24 | $52.86 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EZA trades at $64.63, up 0.98% on the day, but technical indicators signal a bearish trend with moving averages pointing lower. The stock faces resistance near $65 and has support at $63. A dividend of $1.43 is scheduled for payment on June 22, 2026. Recent news highlights South Africa's extended fuel tax cut, which may impact regional economic conditions relevant to the fund's holdings.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include exposure to South African economic policies and commodity volatility. Investors should await updated financials for a clearer valuation picture, as current metrics are unavailable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
